Excalipoint Therapeutics

Excalipoint Therapeutics is a Shanghai-based biotechnology company developing next-generation T‑cell engager (TCE) therapies for oncology and autoimmune diseases. It advances a pipeline of trispecific and pro‑TCE platforms and funds development through venture financing, strategic partnerships and out‑licensing. Key differentiators include trispecific antibodies, TOPAbody/Pro‑TCE masking and T‑Cell Immune Shield technologies aimed at improving efficacy and safety in solid tumors.